Moleculin Biotech, Inc. - 8-K Filing
Moleculin Biotech announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting, scheduled from May 29 to June 2. The study analyzed 78 patients and found no statistically significant change in left ventricular ejection fraction (LVEF) despite high cumulative doses of L-Annamycin. (Items: 7.01 Regulation FD Disclosure On May 21, 2026, Moleculin Biotech, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $MBRX